cheynew
3 years ago
Item 1.01 Entry into a Material Definitive Agreement.
On March 22, 2022, Biotricity, Inc. (the “Company”) entered into an At The Market Offering Agreement, or the ATM Agreement, with H.C. Wainwright & Co., LLC, as sales agent, pursuant to which we may offer and sell, from time to time, through Wainwright shares of our common stock, $0.001 par value per share.
Subject to the terms and conditions of the ATM Agreement, Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell shares from time to time based upon our instructions, including any price, time or size limits specified by us. Under the ATM Agreement, Wainwright may sell shares by any method deemed to be an “at the market” offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, including in privately negotiated transactions. Wainwright’s obligations to sell shares under the ATM Agreement are subject to satisfaction of certain conditions. The Company will pay Wainwright a commission of 3% of the aggregate gross proceeds from each sale of shares and has agreed to provide Wainwright with customary indemnification and contribution rights. We also agreed to reimburse Wainwright for certain specified expenses of up to $50,000.
We are not obligated to make any sales of our common stock under the ATM Agreement and no assurance can be given that we will sell any shares under the ATM Agreement, or, if we do, as to the price or amount of shares that we will sell, or the dates on which any such sales will take place. The ATM Agreement will terminate upon the earlier of (i) the sale of all shares under the ATM Agreement, or (ii) as provided therein.
Sales of shares of common stock under the ATM Agreement will be made pursuant to the registration statement on Form S-3 (File No. 333-255544), which was declared effective by the U.S. Securities and Exchange Commission, or SEC, on May 4, 2021, and a related prospectus supplement filed with the SEC on March 22, 2022, for an aggregate offering price of up to $50,000,000.
The foregoing summary of the ATM Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the ATM Agreement, which is filed herewith as Exhibit 10.1.
A copy of the opinion of Sichenzia Ross Ference LLP relating to the legality of the issuance and sale of shares, is attached hereto as Exhibit 5.1 to this current report on Form 8-K.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares under the ATM Agreement, nor shall there be any sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our Annual Report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
5.1 Opinion of Sichenzia Ross Ference LLP.
10.1 At The Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated March 22, 2022.
23.1 Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1).
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
cheynew
3 years ago
BIOTRICITY TO LAUNCH COMMERCIAL SALES OF ITS DISRUPTIVE CARDIAC MONITORING DEVICE, BIOTRES IN APRIL 2022
Company reports pre-order sales from existing customers of its wireless wearable device for early detection of cardiac arrhythmias
REDWOOD CITY, CA / ACCESSWIRE / March 22, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.
Biotres is the Company's revolutionary technology that represents the future of Remote Patient Monitoring and the delivery of real-time diagnostic data. It serves as a three-lead device designed to continuously record electrocardiogram (ECG) data for early detection of cardiac arrhythmias, disrupting the conventional one-lead patch Holter monitor which takes longer analysis time and diagnosis time.
Biotres received FDA 510(k) clearance in January 2022, opening up a new market and expanding Biotricity's total addressable market to $5.7 Billion. Since taking pre-orders last month, the Company has experienced strong demand for Biotres from existing customers. The Company has plans to roll out additional complementary products throughout 2022, following the same approach as Biotres. Each solution will grow the company's TAM, creating new revenue streams for existing customers while expanding its customer base.
Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, commented, "After months of anticipation, our Biotres product is finally available for sale. Judging by the amount of pre-order interest we've seen since February, Biotres can provide millions of individuals with an early detection method to easily and efficiently record cardiac arrhythmias. We are optimally positioned to penetrate a $2 billion-dollar holter market that needs a faster and more efficient approach, critical to improving patient lives."
You can purchase biotres through the following link: https://www.biotricity.com/biotres/
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
CONTACT:
Investor Relations:
Biotricity Inc.
(800) 590-4155
investors@biotricity.com
Media Relations
Erica Fiorini, Russo Partners
(212) 845-4253
Erica.Fiorini@russopartnersllc.com
SOURCE: Biotricity, Inc.
oldstocks
3 years ago
Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias
The Biotres addresses the $2 Billion-dollar holter market
REDWOOD CITY, CA / ACCESSWIRE / January 24, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.
Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO commented, "We are extremely proud of this accomplishment and its potential to reshape the future of cardiac prevention and monitoring with this novel platform. With Biotres receiving 510(k) clearance, we now have another option for providing a secondary product for doctors and hospitals to meet their patients' cardiac monitoring needs. Coupled with the recent successful non-dilutive financing, we believe we are well capitalized to execute the expansion of our commercialization efforts."
"Biotres, is a holter for low-risk patients and is designed for comfort for long-term wear," he added. "Cardiac disease remains a chronic issue, requiring persistent intervention, monitoring and management and we believe Biotres may provide a critical tool for improving patient lives and reducing costs."
Designed to address the current limitations of existing holter monitors technologies, Biotres offers the following feature set:
3 Channel Recording - A wearable holter patch device that can provide continuous 3 channel recording of ECG (heart) data. All other known holter patch devices are 1 channel or 2 channels.
Rechargeable Battery - It can be worn continuously for 48 hours, in connectivity mode, before needing to be charged for 1 hour, enabling continuous data collection for extended periods of time without any intervention, a distinction not possible with traditional holter patch solutions.
Wireless Connectivity - Utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current holter patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.
User-Friendly Design - Easy to understand and comfortable to wear during regular day-to-day activities.
Modular Design - Designed with the flexibility to support our strategy of adding future features and functionality to the Biotres platform.
Unique Business Model - the design of Biotres enables providers to bill directly, creating a revenue stream with a simplified workflow for providers while reducing risk and diagnostic turnaround time for patients.
The Biotres not only expands our product portfolio, it opens up a new market and increases Biotricity's Total Addressable Market from $1B to $5.7 Billion and will be widely available for sale starting April 1, 2022
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
Public Relations
Bospar
prforbiotricity@bospar.com
SOURCE: Biotricity, Inc.
View source version on
accesswire.com
:
https://www.accesswire.com/685114/BiotricityReceives-FDA-510k-Clearance-for-its-Biotres-Cardiac-Monitoring-Device
cheynew
3 years ago
BIOTRICITY COMPLETES $12 MILLION NON-DILUTIVE DEBT FINANCING
Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms
5-year term deal strengthens balance sheet, positions company for multiple new product launches in 2022
REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 / Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced the successful completion of a $12 million non-convertible debt financing.
The $12 million capital infusion terms provided by SWK Funding LLC (NASDAQ:SWKH), an investor in healthcare and life science companies, include two years, interest-only period and a 40% principal balloon payment at the end of its five year term. The intended use of proceeds is to replace existing less favorable debt that is coming due, support the Company's inventory, and finance annual recurring revenue (ARR) subscriptions.
Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO commented, "This capital infusion represents the strength of our recurring revenue business model and validates the confidence in our plan with lenders. It greatly strengthens our capital position in a manner that is non-dilutive to our equity shareholders and eliminates a current debt instrument that carried less favorable terms. This also follows our August equity raise that helped facilitate our Nasdaq listing. As a supplement to our existing capital reserves, this augments our healthy capital base to finance inventory and support our Annual Recurring Revenues (ARR).
"Using debt rather than equity financing allows us to avoid shareholder dilution at this time." Dr. Waqaas added. "We're excited to have the opportunity to aggressively accelerate the execution of our business plan."
In his December 7 Letter to Shareholders, Dr. Al-Siddiq discussed his product roadmap for a full pipeline of revolutionary remote cardiac monitoring devices slated for commercialization in 2022.
Winston Black, CEO of SWK stated, "We strongly believe in the hard and important work Biotricity is doing to revolutionize cardiac health monitoring for the benefit of patients and healthcare practitioners. We are confident that the Company will successfully meet its 2022 commercialization and sales goals on its way to scaling to higher levels of profitability in the years ahead."
Summary Transaction Terms
Net proceeds of $10.18 million were received by the Company, after giving effect to the payment of $274,000 in origination and the repayment of approximately $1.57 million in prior Company indebtedness. In addition, the Company issued the Lender 57,536 warrants convertible into one share of common stock each, with a 7-year term and an exercise price of $6.26.
The Term Loan will accrue interest at a margin of 10.5% plus the greater of 3-month LIBOR or a 1% LIBOR floor, or LIBOR replacement rate, as applicable.
The Term Loan will have an initial interest-only period of 2 years, potentially extendible to 3 years, prior to beginning to amortize, after taking effect of a 40% balloon payment at maturity, and will be subject to customary covenants and reporting obligations on the part of the Company.
Full details of the transaction are available in the Company's report on Form 8-K at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Bioheart does not diagnose, treat, or repair heart disease. Bioheart is not intended to be a diagnostic tool, or for clinical use, or clinical interpretation, and is meant to be a lifestyle and wellness solution for individuals. If users of the Bioheart are concerned about the data obtained from the device, they should consult a medical professional directly for further advice. Biotricity disclaims any representation made, whether explicitly or implicitly, which would suggest the accuracy of the data obtained is suitable for clinical interpretation.
Bioheart as described herein, and subsequent versions, may or may not be the same as advertised and may or may not differ in features and functionality. Any statements made herein in relation to Bioheart, its features, functionality are based on design and concepts that the company believe are achievable, but the functionality may be different.
Bioheart name, logo, and tag lines are trademarks of Biotricity Inc. US and International Patents Pending. Bioheart does not require a prescription.
About SWK Holdings:
SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris Biopharma, whose core Peptelligence™ drug delivery technology creates oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its specialty finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
CONTACTS
Media
Bospar
prforbiotricity@bospar.com
Investor relations
Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348
Mark Forney
MKR Group, Inc.
12198 Ventura Blvd., Suite 200
Los Angeles, CA 91604
mark@mkrir.com
SOURCE: Biotricity Inc.
View source version on accesswire.com:
https://www.accesswire.com/679576/Biotricity-Completes-12-Million-Non-Dilutive-Debt-Financing
Theyahoo
3 years ago
Why the silence here?
REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.
Highlights from the shareholder letter include:
Recent uplisting to Nasdaq that the Company believes will help further attract a larger pool of sophisticated institutional investors, and a potential increase in liquidity and visibility
Commercialization of the personal medical 3-devices kit, Biokit, for integration into the Biotricity ecosystem
Record quarterly revenue of $1.81 million for its 2022 fiscal year's second quarter ended September 30, 2021, up 143% year-over-year - its tenth consecutive quarter of triple-digit year-over-year growth
The product roadmap for Bioflux®, Biotres, Biocare® Telemed, Biokit, and Bioheart
The Company's 2022 goals including launching new state-of-the-art cardiac monitoring solutions and software services.
https://finance.yahoo.com/news/biotricity-leader-remote-cardiac-health-153500945.html
cheynew
3 years ago
Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor
November 10 2021 - 09:45AM
Business Wire
Alert
Print
Share On Facebook
Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone
Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www.bioheart.com.
The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. “Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.
Heart conditions are intermittent, requiring long term data collection for effective insights. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots. Introducing a groundbreaking new capability, users can create snapshots of rhythm data by reviewing past data and marking it for personal records. This is a first-of-its-kind feature that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.
Bioheart features include:
With the Bioheart smartphone app, users can:
Built-in dry contacts for data collection
Advanced data collection – three different heart views
24/7 continuous rhythm monitoring
48 hour battery life
Personalized analytics
Bluetooth connected
View electrical heart rhythm live on the app
View data on advanced heart metrics such as electrical heart rhythm, heart rate and heart rate variability
View historical heart rate ranges
Create a heart rhythm diary and save snapshots of heart activity
Easily create retrospective snapshots, a first-of-its kind capability
Easily export and share heart data with a physician
Bioheart incorporates the Company’s proprietary advanced heart technology, combined with powerful analytics and continuous rhythm monitoring, to help individuals understand and improve their heart health. It provides 24/7 electrical heart rhythm monitoring and recording with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.
“Bioheart combines unparalleled accuracy in a heart monitoring device with continuous data, advanced heart health insights, and powerful features tailored to individuals at risk for heart disease or who want precise data for performance tracking, optimization and preventative cardiac wellness,” said Dr. Al-Siddiq. “Bioheart furthers Biotricity’s mission of developing revolutionary healthcare solutions that help engage and empower individuals to take control of their health, starting with the deadliest chronic disease and one of healthcare’s largest cost drivers: cardiac disease.”
Heart condition signs are typically intermittent, and most heart monitoring devices only capture short periods of heart activity. These devices have limited capabilities and do not provide individuals with the heart data or tools needed to support preventative care and effective lifestyle improvements. With Bioheart’s continuous monitoring and long-term data collection approach, users can analyze heart data from previous months, well after the initial recording, to understand changes and long-term trends.
“Bioheart has the potential to make an immediate, life-changing impact for those who use it,” added Dr. Al-Siddiq. “As a direct manufacturer, we’re thrilled to have been able to accelerate our market delivery to the general market in less than a year, ahead of schedule and in time for the busy holiday gifting season.”
Bioheart retails for $199 and is available for purchase here or at www.bioheart.com. The app is available on Apple’s App Store and on Google Play.
You can see Bioheart in action here.
About Biotricity
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Bioheart name, logo, and tag lines are trademarks of Biotricity Inc. US and International Patents Pending. Bioheart does not require a prescription.
Bioheart does not diagnose, treat, or repair heart disease. Bioheart is not intended to be a diagnostic tool, or for clinical use, or clinical interpretation, and is meant to be a lifestyle and wellness solution for individuals. If users of the Bioheart are concerned about the data obtained from the device, they should consult a medical professional directly for further advice. Biotricity disclaims any representation made, whether explicitly or implicitly, which would suggest the accuracy of the data obtained is suitable for clinical interpretation.
Bioheart as described herein, and subsequent versions, may or may not be the same as advertised and may or may not differ in features and functionality. Any statements made herein in relation to Bioheart, its features, functionality are based on design and concepts that the company believe are achievable, but the functionality may be different.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux, Bioheart, Biokit or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005751/en/
Media contacts
Bospar
prforbiotricity@bospar.com
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348
Mark Forney
MKR Group, Inc.
12198 Ventura Blvd., Suite 200
Los Angeles, CA 91604
mark@mkrir.com
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ask ADVFN Intelligence (AI)
trader_ron
3 months ago
Renee
3 months ago
glenn1919
6 months ago
Monksdream
7 months ago
AJ Freely
1 year ago
Gotham Bay Group
2 years ago
bud_fox
2 years ago
starkd748
2 years ago
wesley_
3 years ago
TrendTrade2016
3 years ago
Hot Features
Premium
